Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17100805 | 0.87 | DHODH (0.41) | DHODHS1PR1MAPT | |
| SCHEMBL17100823 | 0.85 | DHODH (0.37) | DHODHMEN1MAPTKMT2A | |
| SCHEMBL17100849 | 0.84 | DHODH (0.38) | DHODH | |
| SCHEMBL17100925 | 0.83 | DHODH (0.38) | DHODH | |
| SCHEMBL17100760 | 0.83 | S1PR1 (0.36) | DHODHS1PR1MEN1MAPTKMT2A | |
| SCHEMBL17100863 | 0.83 | DHODH (0.35) | DHODHS1PR1ARMEN1MAPT | |
| SCHEMBL17100807 | 0.83 | DHODH (0.37) | DHODH | |
| SCHEMBL17100998 | 0.80 | MAPT (0.44) | DHODHMEN1MAPTKMT2A | |
| SCHEMBL17100845 | 0.77 | DHODH (0.36) | DHODHMEN1MAPTKMT2A | |
| SCHEMBL17100883 | 0.76 | DHODH (0.42) | DHODHMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088513-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2017-03-30 | — | — | US | claimed |
| EP-3119744-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | Algiax Pharmaceuticals GmbH (DE) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140081-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2015-09-24 | — | — | WO | claimed |
| US-12161695-B2 | GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells | DIAMYD MEDICAL AB (SE) | 2024-12-10 | — | — | US | disclosed |
| US-20210113586-A1 | NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES | DIAMYD MEDICAL AB (SE) | 2021-04-22 | — | — | US | disclosed |
| EP-3755314-A1 | GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS | Diamyd Medical AB (SE) | 2020-12-30 | — | — | EP | disclosed |
| EP-3756007-A1 | NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES | Diamyd Medical AB (SE) | 2020-12-30 | — | — | EP | disclosed |
| US-20200384086-A1 | GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS | DIAMYD MEDICAL AB (SE) | 2020-12-10 | — | — | US | disclosed |
| US-10472324-B2 | 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives | ALGIAX PHARMACEUTICALS GMBH (DE) | 2019-11-12 | — | — | US | disclosed |
| WO-2019162403-A1 | GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS | DIAMYD MEDICAL AB (SE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019164446-A1 | NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES | DIAMYD MEDICAL AB (SE) | 2019-08-29 | — | — | WO | disclosed |
| US-20170088513-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2017-03-30 | — | — | US | disclosed |
| EP-3119744-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | Algiax Pharmaceuticals GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140081-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088513-A1 | 2-CYANO-3-CYCLOPROPYL-3-HYDROXY-N-ARYL-THIOACRYLAMIDE DERIVATIVES | GABRA3, GABRA2, GABRB3 | DHODH 3129/4885S1PR1 2467/4885AR 881/4885 |
| US-10472324-B2 | 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives | GABRA3, GABRA2, GABRB3 | DHODH 3129/4885S1PR1 2467/4885AR 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.